Trevi Therapeutics (TRVI) Income from Non-Controlling Interests (2022 - 2026)
Trevi Therapeutics' (TRVI) quarterly Income from Non-Controlling Interests came in at -$338000.0 in Q1 2026, down 2916.67% year-on-year from $12000.0 in Q1 2025, and down 2916.67% quarter-over-quarter from $12000.0 in Q1 2025.
Trevi Therapeutics (TRVI) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Trevi Therapeutics' Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at -$338000.0 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | - |
| 10 | Trevi Therapeutics | 2.61 Bn | 2.61 Bn | - | -338,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -338,000.00 |
| Mar 31, 2025 | 12,000.00 |
| Sep 30, 2022 | -128,000.00 |
| Jun 30, 2022 | -135,000.00 |